The latest price target for Apogee Therapeutics (NASDAQ:APGE) was reported by Mizuho on March 30, 2026. The analyst firm set a price target for $110.00 expecting APGE to rise to within 12 months (a possible 27.91% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Apogee Therapeutics (NASDAQ:APGE) was provided by Mizuho, and Apogee Therapeutics maintained their outperform rating.

There is no last upgrade for Apogee Therapeutics

The last downgrade for Apogee Therapeutics Inc happened on January 22, 2026 when RBC Capital changed their price target from $70 to $83 for Apogee Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apogee Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apogee Therapeutics was filed on March 30, 2026 so you should expect the next rating to be made available sometime around March 30, 2027.

While ratings are subjective and will change, the latest Apogee Therapeutics (APGE) rating was a maintained with a price target of $105.00 to $110.00. The current price Apogee Therapeutics (APGE) is trading at is $86.00, which is out of the analyst’s predicted range.